Alive, deceased, or unreachable participants (as permitted by local regulation), aged ≥18 years at the start of first-line treatment for BPDCN, and treated with chemotherapy regimens (at a minimum) as first-line treatment for BPDCN from May 2016
Diagnosed with BPDCN, based on clinical, laboratory, and imaging (where performed per institutional practice) assessments, with a demonstration of a specific immunophenotype (either by immunohistochemistry or flow cytometry), particularly CD4, CD56, and CD123
Participants (or their legally authorized representatives) who have signed the informed consent and privacy form, where required as per local regulation
You may not be if
Participant has received an investigational agent as first-line therapy for BPDCN
Participant has received first-line therapy for BPDCN in an interventional clinical trial
